ClinicalTrials.gg
RecruitingNCT07513077Updated Apr 6, 2026

Prevention of Noise-Induced Hearing Loss in Primary Education

An interventional study of HoorToren educational package in Effectiveness of Application Education Intervention, Noise Induced Hearing Loss and Behavior Change Interventions, sponsored by Erasmus Medical Center. Recruiting at 1 site in Netherlands. Per ClinicalTrials.gov, last updated 2026-04-06.

Sponsored by Erasmus Medical Center · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
600
Allocation
Randomized
Sex
All
01

Study summary

The goal of this randomized controlled trial is to evaluate the effectiveness of the educational program the HoorToren in promoting recreational safe listening behavior among Dutch primary school children in group 7 (aged 10-11 years) and thereby contribute to preventing noise-induced hearing loss. The main objectives are:

  • To evaluate the HoorToren's effects on promoting the child's safe listening behavior when using headphones or earbuds. Both safe listening and its psychological determinants will be measured.
  • To evaluate the HoorToren's effects on parents' perception of their child's safe listening behaviors. The effects on parental behavior promoting or facilitating their child's safe listening behavior, including its psychological determinants, will also be evaluated.

Researchers will compare children who receive lessons from the HoorToren educational program, and their parents (intervention group) with children and their parents who do not receive the lessons (control group) to evaluate the effectiveness of the HoorToren. Outcomes will be assessed using newly developed and validated self-report questionnaires for both children and their parents. Additionally, the child's listening behavior will be measured via a smartphone application installed on the child's phone. Measurements will take place at four time points during the school year.

Read the detailed description

Results of the currently pending validation study will decide how the primary outcome (the child´s listening behavior) will eventually be defined, i.e. based on the child's versus the parent's report. The child's listening behavior as measured via the smartphone app is an important secondary outcome.

02

Conditions studied

  • Effectiveness of Application Education Intervention
  • Noise Induced Hearing Loss
  • Behavior Change Interventions
  • Primary School Children

Keywords

  • Noise-induced hearing loss
  • Prevention
  • Primary school
  • Randomized controlled trial
  • Effectiveness
03

In context

Hearing Loss, Noise-Induced

46 studies on the registry are indexed under Hearing Loss, Noise-Induced; 10 are open to participants now.

This study's planned enrollment of 600 is above the median of 88 across 30 interventional studies indexed under Hearing Loss, Noise-Induced.

Browse Hearing Loss, Noise-Induced studies →

Lead sponsor

Erasmus Medical Center is the lead sponsor of 479 studies on the registry; 182 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For schools: None.

For children:

  • Dutch primary school children in group 7 (corresponding to Year 6 in the UK).
  • from legally authorized parent(s) or guardian(s).

Parents:

  • Child is participating.

Exclusion criteria

Exclusion Criteria:

For schools:

  • HoorToren package has been taught at group 6 in the previous school year.

For children:

  • Children without from legally authorized parent(s) or guardian(s).
  • Children who cannot read and write Dutch.

For parents:

  • Parents who cannot read and write Dutch
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
600 participants (estimated)

Study arms

  • Experimental
    Intervention arm

    In this arm students receive seven lessons of the educational program the HoorToren, including 4 home assignments also targeting parents.

    Other: HoorToren educational package

  • No intervention
    Control arm

    In this arm students receive no lessons of the educational program the HoorToren.

Interventions

  • OtherHoorToren educational package

    Educational program, consisting of 7 classroom lessons for group 7. Each lesson has an average duration of 30-45 minutes. Parents are targeted in 4 home assignments for the children.

06

What researchers measure

Primary outcomes

  1. The primary outcome is the child's recreational listening behavior when using earbuds or headphones, as reported by either the child or a parent (pending the validation study).

    The primary outcome measure will be assessed using newly developed and validated self-report questionnaires for children and parents. The final primary outcome (i.e. either child or parent-reported) will be chosen based on the pending validation study. The outcome will include a composite variable based on the self-reported listening duration and volume. The exact definition will depend on the validation study.

    Time frame: The measurements will take place at the start of the study (baseline, i.e., pre-intervention), immediately post-intervention (2 months after baseline), 3 months post-intervention, and 7 months post-intervention.

Secondary outcomes

  1. The child's recreational safe listening behavior when using earbuds or headphones with their own smartphone.

    This outcome will be objectively measured with a newly developed smartphone application. The composite variable that will be included will be based on the registered listening duration and volume. The exact definition will depend on the validation study.

    Time frame: The measurements will take place at the start of the study (baseline, i.e., pre-intervention), immediately post-intervention (2 months after baseline), 3 months post-intervention, and 7 months post-intervention.

  2. The child's psychological determinants of safe listening behavior.

    These outcomes will be measured using newly developed and validated self-report questionnaires, and are pending the validation study. Examples of determinants are risk perception (susceptibility to, severity of noise-induced hearing loss (NIHL)) and capacity to apply the safe listening behavior.

    Time frame: The measurements will take place at the start of the study (baseline, i.e., pre-intervention), immediately post-intervention (2 months after baseline), 3 months post-intervention, and 7 months post-intervention.

  3. Parents' psychological determinants related to promoting or facilitating safe listening behavior in their child.

    These outcomes will be measured using newly developed and validated self-report questionnaires, and are pending the validation study. Examples of determinants are risk perception (child susceptibility to, severity of NIHL) and capacity to facilitate the child's safe listening behavior.

    Time frame: The measurements will take place at the start of the study (baseline, i.e., pre-intervention), immediately post-intervention (2 months after baseline), 3 months post-intervention, and 7 months post-intervention.

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for Aug 2027, 17 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2026
First posted
Apr 6, 2026
StartActual
Mar 30, 2026
Primary completionEst.
Aug 2027
CompletionEst.
Aug 2027
Last update
Apr 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07513077
Responsible party
Marc P. van der Schroeff (MD, PhD, associate professor, Erasmus Medical Center) — Principal investigator
First posted
Apr 6, 2026
Start date
Mar 30, 2026
Primary completion
Aug 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Apr 6, 2026

Study contacts

Willemijn van Diemen, Master of science.
Contact
w.vandiemen@erasmusmc.nl
(+31) 06 42 98 71 24
Marc van der Schroeff, dr.
Contact
m.vanderschroeff@erasmusmc.nl

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion